Skip to main content
Equibles
STEK logo

STEK · Stemtech Corp

Track STEK — free

Use STEK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.00 +0.00 (+0.00%) At close · Sep 3
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has experienced recurring net losses and negative cash flows from operations since inception and has an accumulated deficit of approximately $36.3 million and a working capital deficiency of approximately $10.5 million at June 30, 2026. The Company has funded its activities to date almost exclusively from debt and equity financing. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$299,703
Shares
3.00B

STEK metrics

63 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$299,703

Price action

19 metrics
Price change (1W)
+0.0%
Price change (30D)
+0.0%
Price change (3M)
-50.0%
Price change (6M)
-50.0%
Price change (YTD)
-87.5%
Price change (1Y)
-99.3%
Trailing year
Price change (5Y)
—
52-week high
$0.02
52-week low
$0.00
Change from 52-week high
-99.5%
Change from 52-week low
+0.0%
Annualized volatility
450.7%
Beta
-0.3
RSI (14D)
40.2
Price vs SMA 50
-12.3%
Price vs SMA 200
-84.0%
Avg volume (3M)
34.84M
Relative volume
0.1
Average dollar volume
$3,845

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
3.00B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.9×
reciprocal yield 54.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 801.7%
P / book
—
FCF yield
-109.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,282.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.6×
reciprocal yield 63.6%
EV / revenue historical average (5Y)
1.6×
reciprocal yield 63.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
77.3%
Operating margin
-100.8%
Trailing 12 months
Net margin
-160.0%
Gross profit (TTM)
$1.86M
Operating profit (TTM)
−$2.42M
Net income (TTM)
−$3.84M
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
-13.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.03

Growth

11 metrics
Revenue growth YoY
-9.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.40M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,358.4%
Year over year · more shares
Revenue CAGR (3Y)
-14.2%
Revenue CAGR (5Y)
-8.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-121.5%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$2.26M
Free cash flow (TTM)
−$328,755
Quick ratio
0.0
Interest coverage
-1.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$4.15M
Latest balance sheet
Cash & equivalents
$246,772
Total assets
$3.16M
Total debt
$4.40M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$328,755
Capital expenditures (TTM)
$0
R&D (TTM)
$0
SG&A (TTM)
—
Stock compensation (TTM)
$439,055
R&D / revenue
0.0%
Stock compensation / revenue
18.3%

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1511820 CUSIP 85859W102 Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)